Population studies have reported that proton-pump inhibitors (PPIs) increase cardiovascular mortality, at least in part owing to an increased propensity for life-threatening arrhythmias, but these findings have largely been ignored. We propose a series of recommendations for prescribers of PPIs to ensure a balance of the benefits against the potential arrhythmic risks.
- Pietro Enea Lazzerini
- Riccardo Accioli
- Maurizio Acampa
